title: Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes.
abstract: Physiological hypertrophy represents the adaptive changes of the heart required for supporting the increased hemodynamic load in regularly trained healthy subjects. Mechanisms responsible for the athlete's hypertrophy still remain unknown. In 15 trained competitive soccer players and in 15 healthy men not engaged in sporting activities (sedentary control subjects) of equivalent age, we investigated the relationship among cardiac growth factor formation, cardiac sympathetic activity, and left ventricular morphology and function. Cardiac formation of insulin-like growth factor (IGF)-I, endothelin (ET)-1, big ET-1, and angiotensin (Ang) II was investigated at rest by measuring artery-coronary sinus concentration gradients. Cardiac sympathetic activity was studied by [(3)H]norepinephrine (NE) kinetics. Cardiac IGF-I, but not ET-1, big ET-1, and Ang II, formation was higher in athletes than in control subjects (P<0.01). NE levels in arterial and peripheral venous blood did not differ between groups. In contrast, coronary sinus NE concentration was higher in athletes than in control subjects (P<0.01). Cardiac, but not total systemic, NE spillover was also increased in athletes (P<0.01), whereas cardiac [(3)H]NE reuptake and clearance were not different. Echocardiographic modifications indicated a volume overload-induced hypertrophy associated with increased myocardial contractility. Multivariate stepwise analysis selected left ventricular mass index as the most predictive independent variable for cardiac IGF-I formation and velocity of circumferential fiber shortening for cardiac NE spillover. In conclusion, increased cardiac IGF-I formation and enhanced sympathetic activity selectively confined to the heart appear to be responsible for the physiological hypertrophy in athletes performing predominantly isotonic exercise.
authors.affiliation: Clinica Medica Generale e Cardiologia, University of Florence, Italy. gg.neriserneri@dfc.unifi.it
authors.forename: G G
authors.initials: GG
authors.lastname: Neri Serneri
authors.forename: M
authors.initials: M
authors.lastname: Boddi
authors.forename: P A
authors.initials: PA
authors.lastname: Modesti
authors.forename: I
authors.initials: I
authors.lastname: Cecioni
authors.forename: M
authors.initials: M
authors.lastname: Coppo
authors.forename: L
authors.initials: L
authors.lastname: Padeletti
authors.forename: A
authors.initials: A
authors.lastname: Michelucci
authors.forename: A
authors.initials: A
authors.lastname: Colella
authors.forename: G
authors.initials: G
authors.lastname: Galanti
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000096:biosynthesis; D004452:Echocardiography; D015444:Exercise / Q000502:physiology*; D006321:Heart / Q000294:innervation*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000503:physiopathology*; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000097:blood; D012916:Soccer; D013564:Sympathetic Nervous System / Q000503:physiopathology*
chemical_list: D000804:Angiotensin II; D007334:Insulin-Like Growth Factor I; D009638:Norepinephrine